Meta-analysis of six-month memantine trials in Alzheimer's disease
Meta-analysis of six-month memantine trials in Alzheimer's disease
复制标题
DOI：
10.1016/j.jalz.2006.10.004
复制
发表时间：
2007-01-01
影响因子：
14
通讯作者：
Graham, Stephen M.
中科院分区：
文献类型：
--
作者：
Doody, Rachelle Smith;Tariot, Pierre N.;Graham, Stephen M.
背景：临床试验表明美金刚对阿尔茨海默病（AD）的所有阶段都有益处。甲氨蝶呤可能AD门诊患者的试验进行了meta分析：六个随机，安慰剂对照试验符合纳入标准。认知，全球，功能，行为和安全措施进行了评价，使用固定或随机效应模型。进行敏感性分析，以确定潜在的影响，疾病的严重程度和伴随胆碱酯酶抑制剂use.Results：总体而言，美金刚胺显示统计学显着，同质效益的全球和功能的结果和统计学显着，但异质性的好处认知。在汇总的中重度AD研究中，对总体、功能和行为指标的影响显著且均匀;在汇总的轻度至中度研究中，对总体评分和认知的影响显著且均匀。安全配置文件建议优秀的安全性和耐受性，严重程度groups.Conclusions之间没有差异：美金刚始终受益于患者在AD的各个阶段，耐受性良好。(C)2007年，阿尔茨海默氏症协会。All rights reserved.
Background: Clinical trials have suggested benefits of memantine for all stages of Alzheimer's disease (AD). A rneta-analysis of memantine trials in outpatients with probable AD was conducted.Methods: Six randomized, placebo-controlled trials fulfilled inclusion criteria. Cognitive, global, functional, behavioral, and safety measures were evaluated by using fixed or random effects models. Sensitivity analysis was performed to determine potential effects of disease severity and concomitant cholinesterase inhibitor use.Results: Overall, memantine showed statistically significant, homogenous benefits on global and functional outcomes and statistically significant but heterogeneous benefit on cognition. In pooled moderate to severe AD studies, effects were significant and homogeneous on global, functional, and behavioral measures; in pooled mild to moderate studies, significant and homogeneous effects were found on global rating and cognition. Safety profiles suggested excellent safety and tolerability, with no differences between the severity groups.Conclusions: Memantine consistently benefited patients in all stages of AD and was well-tolerated. (C) 2007 The Alzheimer's Association. All rights reserved.